Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Abstract BACKGROUND: Globally, breast cancer is considered one of the most common cancers among women and the second most common cancer worldwide. Breast cancer is also more common in developed countries, and its prevalence is increasing globally by 2% each year. AIM: The aim of this study is to determine the features of the state of cellular and humoral markers of the immune system, as well as the relationship of specific and nonspecific immunity in women in the compared groups in breast cancer in Aktobe region. METHODS: The study was conducted on 251 patients at Medical Center of West Kazakhstan Marat Ospanov Medical University with the established diagnosis of breast cancer. The study period was 3 years (2018-2020). Acknowledgements. Authors declare the absence of conflict of interest. The study is funded by the Ministry of Education and Science of the Republic of Kazakhstan project IRN 0118RK01065. Two groups of patients were formed, among them in the control group - BC before chemotherapy and in the main group - BC after chemotherapy. To address the objectives, in addition to the general clinical study, all patients were conducted immune system study. CD3+CD19-, CD3-CD19+, CD4+CD8-,CD4-CD8+, IRI, CD3+HLA-DR+, NK(CD16+56+), CD3+/CD16+56+ ; and to determine humoral immunity, the content of JgM, JgG, JgA were determined. RESULTS: Correlation analysis revealed a strong positive relationship between IRI and T helper (CD4+CD8-) (r=0.79; p≤0.05) and a strong negative correlation between T cytotoxic lymphocyte (CD4-CD8+) and IRI (r= -0.8; p≤0.05) in both patient groups. The ratio of the two T cell subpopulations CD4+/T cell CD8+ is at the regulatory T cell level (IRI). A direct median correlation between T lymphocyte (CD3+CD19-) and T killer (CD3+/CD16+56+) r= 0.35; (p≤0.05) was found, which indicates an integral regulatory role of natural killer cells in immune system function. The following coorelation analysis showed a weak negative association between cellular and humoral immunity in the control group of women between T cytotoxic lymphocytes (CD4-CD8+) and IgG(r=-0.2; p≤0.05). Further, the relationship revealed between cellular and humoral immunity in the main group between IG M and NK cells (r= -0.2; p≤0.05). CONCLUSION: It can be assumed that identifying the possibility of altering the antitumor immune response before and after chemotherapy in patients with a primary breast tumor may set the stage for its early detection and application of targeted chemoprophylaxis. Abstract BACKGROUND: Globally, breast cancer is considered one of the most common cancers among women and the second most common cancer worldwide. Breast cancer is also more common in developed countries, and its prevalence is increasing globally by 2% each year. AIM: The aim of this study is to determine the features of the state of cellular and humoral markers of the immune system, as well as the relationship of specific and nonspecific immunity in women in the compared groups in breast cancer in Aktobe region. METHODS: The study was conducted on 251 patients at Medical Center of West Kazakhstan Marat Ospanov Medical University with the established diagnosis of breast cancer. The study period was 3 years (2018-2020). Acknowledgements. Authors declare the absence of conflict of interest. The study is funded by the Ministry of Education and Science of the Republic of Kazakhstan project IRN 0118RK01065. Two groups of patients were formed, among them in the control group - BC before chemotherapy and in the main group - BC after chemotherapy. To address the objectives, in addition to the general clinical study, all patients were conducted immune system study. CD3+CD19-, CD3-CD19+, CD4+CD8-,CD4-CD8+, IRI, CD3+HLA-DR+, NK(CD16+56+), CD3+/CD16+56+ ; and to determine humoral immunity, the content of JgM, JgG, JgA were determined. RESULTS: Correlation analysis revealed a strong positive relationship between IRI and T helper (CD4+CD8-) (r=0.79; p≤0.05) and a strong negative correlation between T cytotoxic lymphocyte (CD4-CD8+) and IRI (r= -0.8; p≤0.05) in both patient groups. The ratio of the two T cell subpopulations CD4+/T cell CD8+ is at the regulatory T cell level (IRI). A direct median correlation between T lymphocyte (CD3+CD19-) and T killer (CD3+/CD16+56+) r= 0.35; (p≤0.05) was found, which indicates an integral regulatory role of natural killer cells in immune system function. The following coorelation analysis showed a weak negative association between cellular and humoral immunity in the control group of women between T cytotoxic lymphocytes (CD4-CD8+) and IgG(r=-0.2; p≤0.05). Further, the relationship revealed between cellular and humoral immunity in the main group between IG M and NK cells (r= -0.2; p≤0.05). CONCLUSION: It can be assumed that identifying the possibility of altering the antitumor immune response before and after chemotherapy in patients with a primary breast tumor may set the stage for its early detection and application of targeted chemoprophylaxis. Abstract BACKGROUND: Globally, breast cancer is considered one of the most common cancers among women and the second most common cancer worldwide. Breast cancer is also more common in developed countries, and its prevalence is increasing globally by 2% each year. AIM: The aim of this study is to determine the features of the state of cellular and humoral markers of the immune system, as well as the relationship of specific and nonspecific immunity in women in the compared groups in breast cancer in Aktobe region. METHODS: The study was conducted on 251 patients at Medical Center of West Kazakhstan Marat Ospanov Medical University with the established diagnosis of breast cancer. The study period was 3 years (2018-2020). Acknowledgements. Authors declare the absence of conflict of interest. The study is funded by the Ministry of Education and Science of the Republic of Kazakhstan project IRN 0118RK01065. Two groups of patients were formed, among them in the control group - BC before chemotherapy and in the main group - BC after chemotherapy. To address the objectives, in addition to the general clinical study, all patients were conducted immune system study. CD3+CD19-, CD3-CD19+, CD4+CD8-,CD4-CD8+, IRI, CD3+HLA-DR+, NK(CD16+56+), CD3+/CD16+56+ ; and to determine humoral immunity, the content of JgM, JgG, JgA were determined. RESULTS: Correlation analysis revealed a strong positive relationship between IRI and T helper (CD4+CD8-) (r=0.79; p≤0.05) and a strong negative correlation between T cytotoxic lymphocyte (CD4-CD8+) and IRI (r= -0.8; p≤0.05) in both patient groups. The ratio of the two T cell subpopulations CD4+/T cell CD8+ is at the regulatory T cell level (IRI). A direct median correlation between T lymphocyte (CD3+CD19-) and T killer (CD3+/CD16+56+) r= 0.35; (p≤0.05) was found, which indicates an integral regulatory role of natural killer cells in immune system function. The following coorelation analysis showed a weak negative association between cellular and humoral immunity in the control group of women between T cytotoxic lymphocytes (CD4-CD8+) and IgG(r=-0.2; p≤0.05). Further, the relationship revealed between cellular and humoral immunity in the main group between IG M and NK cells (r= -0.2; p≤0.05). CONCLUSION: It can be assumed that identifying the possibility of altering the antitumor immune response before and after chemotherapy in patients with a primary breast tumor may set the stage for its early detection and application of targeted chemoprophylaxis.
Abstract BACKGROUND: Globally, breast cancer is considered one of the most common cancers among women and the second most common cancer worldwide. Breast cancer is also more common in developed countries, and its prevalence is increasing globally by 2% each year. AIM: The aim of this study is to determine the features of the state of cellular and humoral markers of the immune system, as well as the relationship of specific and nonspecific immunity in women in the compared groups in breast cancer in Aktobe region. METHODS: The study was conducted on 251 patients at Medical Center of West Kazakhstan Marat Ospanov Medical University with the established diagnosis of breast cancer. The study period was 3 years (2018-2020). Acknowledgements. Authors declare the absence of conflict of interest. The study is funded by the Ministry of Education and Science of the Republic of Kazakhstan project IRN 0118RK01065. Two groups of patients were formed, among them in the control group - BC before chemotherapy and in the main group - BC after chemotherapy. To address the objectives, in addition to the general clinical study, all patients were conducted immune system study. CD3+CD19-, CD3-CD19+, CD4+CD8-,CD4-CD8+, IRI, CD3+HLA-DR+, NK(CD16+56+), CD3+/CD16+56+ ; and to determine humoral immunity, the content of JgM, JgG, JgA were determined. RESULTS: Correlation analysis revealed a strong positive relationship between IRI and T helper (CD4+CD8-) (r=0.79; p≤0.05) and a strong negative correlation between T cytotoxic lymphocyte (CD4-CD8+) and IRI (r= -0.8; p≤0.05) in both patient groups. The ratio of the two T cell subpopulations CD4+/T cell CD8+ is at the regulatory T cell level (IRI). A direct median correlation between T lymphocyte (CD3+CD19-) and T killer (CD3+/CD16+56+) r= 0.35; (p≤0.05) was found, which indicates an integral regulatory role of natural killer cells in immune system function. The following coorelation analysis showed a weak negative association between cellular and humoral immunity in the control group of women between T cytotoxic lymphocytes (CD4-CD8+) and IgG(r=-0.2; p≤0.05). Further, the relationship revealed between cellular and humoral immunity in the main group between IG M and NK cells (r= -0.2; p≤0.05). CONCLUSION: It can be assumed that identifying the possibility of altering the antitumor immune response before and after chemotherapy in patients with a primary breast tumor may set the stage for its early detection and application of targeted chemoprophylaxis. Abstract BACKGROUND: Globally, breast cancer is considered one of the most common cancers among women and the second most common cancer worldwide. Breast cancer is also more common in developed countries, and its prevalence is increasing globally by 2% each year. AIM: The aim of this study is to determine the features of the state of cellular and humoral markers of the immune system, as well as the relationship of specific and nonspecific immunity in women in the compared groups in breast cancer in Aktobe region. METHODS: The study was conducted on 251 patients at Medical Center of West Kazakhstan Marat Ospanov Medical University with the established diagnosis of breast cancer. The study period was 3 years (2018-2020). Acknowledgements. Authors declare the absence of conflict of interest. The study is funded by the Ministry of Education and Science of the Republic of Kazakhstan project IRN 0118RK01065. Two groups of patients were formed, among them in the control group - BC before chemotherapy and in the main group - BC after chemotherapy. To address the objectives, in addition to the general clinical study, all patients were conducted immune system study. CD3+CD19-, CD3-CD19+, CD4+CD8-,CD4-CD8+, IRI, CD3+HLA-DR+, NK(CD16+56+), CD3+/CD16+56+ ; and to determine humoral immunity, the content of JgM, JgG, JgA were determined. RESULTS: Correlation analysis revealed a strong positive relationship between IRI and T helper (CD4+CD8-) (r=0.79; p≤0.05) and a strong negative correlation between T cytotoxic lymphocyte (CD4-CD8+) and IRI (r= -0.8; p≤0.05) in both patient groups. The ratio of the two T cell subpopulations CD4+/T cell CD8+ is at the regulatory T cell level (IRI). A direct median correlation between T lymphocyte (CD3+CD19-) and T killer (CD3+/CD16+56+) r= 0.35; (p≤0.05) was found, which indicates an integral regulatory role of natural killer cells in immune system function. The following coorelation analysis showed a weak negative association between cellular and humoral immunity in the control group of women between T cytotoxic lymphocytes (CD4-CD8+) and IgG(r=-0.2; p≤0.05). Further, the relationship revealed between cellular and humoral immunity in the main group between IG M and NK cells (r= -0.2; p≤0.05). CONCLUSION: It can be assumed that identifying the possibility of altering the antitumor immune response before and after chemotherapy in patients with a primary breast tumor may set the stage for its early detection and application of targeted chemoprophylaxis. Abstract BACKGROUND: Globally, breast cancer is considered one of the most common cancers among women and the second most common cancer worldwide. Breast cancer is also more common in developed countries, and its prevalence is increasing globally by 2% each year. AIM: The aim of this study is to determine the features of the state of cellular and humoral markers of the immune system, as well as the relationship of specific and nonspecific immunity in women in the compared groups in breast cancer in Aktobe region. METHODS: The study was conducted on 251 patients at Medical Center of West Kazakhstan Marat Ospanov Medical University with the established diagnosis of breast cancer. The study period was 3 years (2018-2020). Acknowledgements. Authors declare the absence of conflict of interest. The study is funded by the Ministry of Education and Science of the Republic of Kazakhstan project IRN 0118RK01065. Two groups of patients were formed, among them in the control group - BC before chemotherapy and in the main group - BC after chemotherapy. To address the objectives, in addition to the general clinical study, all patients were conducted immune system study. CD3+CD19-, CD3-CD19+, CD4+CD8-,CD4-CD8+, IRI, CD3+HLA-DR+, NK(CD16+56+), CD3+/CD16+56+ ; and to determine humoral immunity, the content of JgM, JgG, JgA were determined. RESULTS: Correlation analysis revealed a strong positive relationship between IRI and T helper (CD4+CD8-) (r=0.79; p≤0.05) and a strong negative correlation between T cytotoxic lymphocyte (CD4-CD8+) and IRI (r= -0.8; p≤0.05) in both patient groups. The ratio of the two T cell subpopulations CD4+/T cell CD8+ is at the regulatory T cell level (IRI). A direct median correlation between T lymphocyte (CD3+CD19-) and T killer (CD3+/CD16+56+) r= 0.35; (p≤0.05) was found, which indicates an integral regulatory role of natural killer cells in immune system function. The following coorelation analysis showed a weak negative association between cellular and humoral immunity in the control group of women between T cytotoxic lymphocytes (CD4-CD8+) and IgG(r=-0.2; p≤0.05). Further, the relationship revealed between cellular and humoral immunity in the main group between IG M and NK cells (r= -0.2; p≤0.05). CONCLUSION: It can be assumed that identifying the possibility of altering the antitumor immune response before and after chemotherapy in patients with a primary breast tumor may set the stage for its early detection and application of targeted chemoprophylaxis.
Breast cancer is the most commonly diagnosed cancer type in women and approximately 700 thousand people around the world lose their lives due to breast cancer every year. Mammography and ultrasound are the techniques that are frequently applied for the diagnosis of breast cancer. However they involve several limitations such as low sensitivity and exposing to high radiation. Additionally, false negative and false positive results could be obtained in conventional diagnostic methods for breast cancer. So it is crucial to generate new diagnostic kits which enable rapid and accurate detection of breast cancer. Antibodies created using hybridoma technology can be considered in the diagnostic kits since they are important tools to bind cancer cell antigens. Although monoclonal antibodies are usually utilized in antibody-mediated diagnostic kits and they possess high specificity in diagnosis and treatment, they conversely indicate low avidity to tumor antigens in comparison to polyclonal antibodies because they can only bind to a single epitope region. Therefore, polyclonal antibodies display a pivotal role in recognition of many epitopes of breast cancer cells. The major aim of this study is to create polyclonal antibodies against whole cell lysate of AU-565 cell line by hybridoma technology and examine their diagnostic value by comparing with conventional antibodies. The acquired tumor cell antigens were supplemented with two distinct adjuvants Complete Freund’s Adjuvant (CFA) and Polyoxidonium (PO) while preparing the formulations for immunization. Thus we also evaluated in vivo immunogenic properties of antigen-adjuvant combinations and compared immunostimulatory efficacies of CFA and PO over prepared antigens. The outputs revealed that whole cell antigens reinforced with CFA demonstrated robust immunostimulatory activities, in vivo by enhancing the produced antibody levels in mice excessively. Polyclonal antibodies that were obtained from spleens of mice immunized with AU-565 cell antigens and CFA combinations were highly effective to capture the antigens that were isolated from different breast cancer cell line. It was detected that obtained polyclonal antibodies exhibited stronger immune reactions with breast cancer antigens when compared with conventional antibodies. Consequently, considerable immunostimulatory performance of AU-565 cell antigens and CFA combination was shown as a vaccine candidate and high diagnostic value of polyclonal antibodies produced in response to vaccination with mentioned formulation was established for the first time in the present study.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.